Aaron Gerds, MD, MS, is an Assistant Professor, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH. Dr Gerds received his undergraduate bachelor’s degree in biology and chemistry from the Hope College, Holland, MI. He then completed his doctorate in medicine at Loyola University Chicago Stritch School of Medicine, Maywood, IL. Dr Gerds stayed on to complete his residency in internal medicine where he gained an interest in hematology and undertook a master’s degree in clinical research methods and epidemiology. He then moved to Seattle to complete his hematology/oncology fellowship at the University of Washington, Fred Hutchinson Cancer Research Center, Seattle, WA.
Dr Gerds has membership for the American Society of Hematology where he is actively involved in the Advocacy Leadership Institute and Clinical Research Training Institute, whilst also serving on the committee for Test Materials Development. Dr Gerds has obtained several awards, namely the Sigma Xi Senior Research Award in 2002, the Alpha Omega Alpha Award in 2010, and the New Investigator Award in 2013.
Speaking on myelodysplastic syndromes and myeloproliferative disorders
Dr Gerds’ research interests lie in myeloproliferative neoplasms, in particular myelofibrosis and its treatments. His recent work has involved clinical trials assessing the efficacy of novel agents such as ruxolitinib and luspatercept.